ArticleCureus2025
Plasmablastic Lymphoma Masquerading as Plasma Cell Myeloma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL) is an uncommon and aggressive type of B-cell lymphoma, and it primarily affects individuals with compromised immune systems, particularly human immunodeficiency virus (HIV)-positive patients. It has a strong predilection for the oral cavity and a high association with Epstein-Barr virus (EBV) infection, with only rare extra-oral and EBV-negative cases. Tumor cells in PBL are represented by immature plasma cells known as plasmablasts, a morphological appearance shared with many B-cell and plasma cell neoplasms, which makes the distinction very challenging among these entities, especially in extra-oral locations and EBV-negative cases. PBL is characterized by an aggressive clinical outcome, with a very poor prognosis. Here, we describe an unusual case involving a 72-year-old patient who was previously diagnosed with plasma cell myeloma, which exhibited unusually aggressive and refractory progression; histomorphological investigations were consistent with an extra-oral, EBV-negative PBL. The rapid disease progression and lymph node involvement along with the presence of plasmablastic morphology raised the suspicion of a PBL. Throughout this case, we highlight the importance of a complete histopathological and immunohistochemical examination with correlation with clinical manifestations to ensure a precise diagnosis, particularly in extra-oral, EBV-negative cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.